INMB
INmune Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INMB
Inmune Bio Inc.
A clinical-stage immunology company that developing immuno therapeutics for the treatment of cancer
225 NE Mizner Blvd, Suite 640, Boca Raton, FL 33432
--
INmune Bio Inc. was originally incorporated in Nevada on September 25, 2015. The company's goal is to develop and commercialize products to treat diseases in which the innate immune system does not work properly or is caused by it. These diseases include cancer, where the lack of activity of NK cells causes the tumor to evade the immune system, MDSCs proliferate to protect the tumor from the patient's immune system, and chronic infections such as dysfunction or other neurological and metabolic diseases, and metabolic diseases caused by chronic inflammation. INmune Bio Inc .'s initial focus is on the treatment of cancer - hematological malignancies and solid tumors.
Earnings Call
Q1/2025
Estimate EPS-0.46
Actual EPS-0.43
Estimate Revenue--
Actual Revenue50.00K
INmune Bio's Q1 2025: Unpacking Contradictions in CORDStrom, EMACC, and Clinical Trial Strategies
May 19,2025 05:09
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
INMB has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected -0.32, beating expectations. The chart below visualizes how INMB has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
